Persistent Pulmonary Hypertension of the Newborn (PPHN)

Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: March 31, 2026Bookmark

Persistent pulmonary hypertension of the newborn (PPHN) is characterized by failure of normal pulmonary vascular transition at birth, leading to increased pulmonary vascular resistance, right-to-left shunting, and severe hypoxaemia despite adequate ventilation.

Types of persistent pulmonary hypertension of the newborn

Type of PPHNPathophysiologyCauses
MaladaptationReflex vasoconstriction of pulmonary arteriolesPerinatal asphyxia, meconium aspiration syndrome (30%), pneumonia, neonatal respiratory distress syndrome (20%), congenital diaphragmatic hernia, hypoxia, acidosis, hypocalcaemia, magnesium, hypothermia
MaldevelopmentMuscularization of pulmonary arteriolesIntrauterine growth restriction (chronic in-utero hypoxia), post-maturity, NSAIDs in pregnancy
UnderdevelopmentDecreased pulmonary arteriolesHypoplastic lungs, congenital diaphragmatic hernia, alveo-capillary dysplasia
Intravascular obstructionIncreased viscosity or obstructionPolycythemia

Pathophysiology pathways of PPHN

PathwayEffectDrugs used to treat
EndothelinVasoconstrictionBosentan
Nitric Oxide – cGMPVasodilationiNO, sildenafil
Prostacyclin-cAMPVasodilationMilrinone, prostaglandins
  • Risk factors
  • Normal vascular transition at birth
    • Lung expansion → reduced pulmonary vascular resistance (PVR)
    • Cord clamping → increased systemic vascular resistance (SVR)
    • Closure of the ductus areteriosus (DA) and the foramen ovale (PFO)
  • Pathophysiology
    • Pulmonary vascular resistance (PVR) remains high
    • Systemic vascular resistance (SVR) is relatively lower than PVR
    • This leads to a persistent right-to-left shunt → reduced pulmonary blood flow → hypoxia
  • Patient History
    • Term or post-term neonate
    • Severe hypoxia with a relatively normal chest radiograph
  • Signs and symptoms
    • Cyanosis refractory to oxygen
    • Labile hypoxia
      • Desaturations occur with handling
    • Tachypnoea
    • Mild respiratory distress
    • Preductal vs postductal SpO2 difference > 5 – 10%
      • Right hand = preductal
      • Foot = post-ductal
    • Loud P2
    • Tricuspid regurgitation murmur
  • Investigations
    • Chest radiograph:
    • Echocardiography: gold standard. Confirms the diagnosis and excludes a congenital heart defect
      • R to L shunt across a patent ductus arteriosus (PDA) or patent foramen ovale (PFO)
      • Right ventricular dilation
      • Septal flattening
      • Tricuspid regurgitation jet – estimates pulmonary pressure
      • Tricuspid regurgitation and pulmonary regurgitation
    • Oxygenation index (OI)
      • 15 = significant disease
      • 20 – 25 = severe disease
      • ≥ 40 = consider ECMO
  • Treatment
    • Minimal handling
    • Maintain temperature, glucose, and calcium
    • Correct acidosis, hypotension, and anaemia (Hb 15 – 16 g/dL0
    • CPAP or mechanical ventilation
    • Optimize oxygenation
      • Target SpO2 92 – 97%
      • Target PaO2 50 – 80 mmHg
      • Avoid hyperoxia
    • Pulmonary vasodilation
      • Inhaled nitric oxide (iNO) is first-line
      • Sildenafil (PDE-5 inhibitor)
      • Mildrinone (PDE-3 inhibitor)
      • Bosentan (endothelin antagonist)
      • Magnesium sulfate
      • Prostacycline
    • Fluids and ionotropes to improve systemic pressure
      • MAP goals of 40 – 45 mmHg
      • This helps to reduce right-to-left shunting
    • ECMO rescue therapy if OI ≥ 40 or if there is refractory hypoxia
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team